NCT01482468

Brief Summary

The purpose of this study is to determine whether continuous infusion of palonosetron after its prophylactic single injection can further reduce the incidence of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
132

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 28, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 30, 2011

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

March 23, 2012

Status Verified

March 1, 2012

Enrollment Period

4 months

First QC Date

November 28, 2011

Last Update Submit

March 21, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • incidence of postoperative nausea and vomiting

    24 hours after surgery

Secondary Outcomes (1)

  • severity of nausea

    for 24 hours after sugery

Study Arms (2)

continuous infusion

ACTIVE COMPARATOR

continuous infusion of palonosetron added to prophylactic single injection of palonosetron

Drug: continuous infusion of palonosetron added to prophylactic single injection of palonosetron

singel injection

PLACEBO COMPARATOR

continuous infusion of normal saline added to prophylactic single injection of palonosetron

Drug: continuous infusion of normal saline added to prophylactic single injection of palonosetron

Interventions

continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg

continuous infusion

continuous infusion of normal saline after single injection of palonosetron 0.075mg

singel injection

Eligibility Criteria

Age20 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA Physical Status 1 or 2
  • Elective gynaecological laparoscopic surgery of ≥ 1h duration

You may not qualify if:

  • Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation
  • Vomiting or retching in the 24 h preceding surgery
  • Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry
  • Ongoing vomiting from gastrointestinal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Incheon St Mary's hospital

Incheon, 403-720, South Korea

RECRUITING

MeSH Terms

Conditions

Postoperative Nausea and Vomiting

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNauseaSigns and Symptoms, DigestiveSigns and SymptomsVomiting

Central Study Contacts

Soo Kyoung Park

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clnical professor

Study Record Dates

First Submitted

November 28, 2011

First Posted

November 30, 2011

Study Start

March 1, 2012

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

March 23, 2012

Record last verified: 2012-03

Locations